Analysis of U.S. Patent 10,195,278 – Scope, Claims, and Patent Landscape
What Does U.S. Patent 10,195,278 Cover?
U.S. Patent 10,195,278, granted on January 29, 2019, to Gilead Sciences, Inc., claims to a specific class of novel prodrugs and their use in treating viral infections. It primarily covers chemical compounds with a core structure linked to specific phosphonate or phosphate groups, intended to serve as antiviral agents, particularly for hepatitis B virus (HBV) and hepatitis C virus (HCV).
The patent emphasizes methods of synthesizing these compounds, their pharmaceutical compositions, and methods of use for treating viral infections. The patent claims are divided into compound claims, composition claims, and method claims.
What Are the Key Claims?
Compound Claims
The patent claims specific chemical entities characterized by a core scaffold with defined substituents, notably including:
- Nucleoside analogs with a phosphonate or phosphate group attached.
- Variations in substituents that influence antiviral activity.
- Specific stereochemistry configurations.
For example, Claim 1 states the compound must have a specified chemical structure, with particular groups at defined positions.
Method of Use Claims
Claims extend to methods of treating HBV or HCV infections with the claimed compounds. This includes administering therapeutically effective doses and treatment regimens.
Composition Claims
Claims cover pharmaceutical compositions comprising the claimed compounds, combined with carriers, diluents, or adjuvants suitable for therapeutic use.
Synthesis and Manufacturing Claims
Some claims specify processes for synthesizing these compounds, involving multiple steps designed to optimize yield, purity, or stereochemical configuration.
Scope Analysis
The patent's scope focuses on a niche of nucleoside phosphonate prodrugs with specific stereochemistry and substitution patterns. It aims to protect both broad classes of compounds and particular representatives, including certain stereoisomers, to prevent competitors from developing similar antivirals.
The claims are moderately broad, targeting a group of compounds rather than a single molecule. However, they are limited to compounds with specific structural features, such as particular phosphonate linkages and stereochemistry.
The scope extends into use methods, making it possible for Gilead to enforce patent rights against both compound manufacture and therapeutic use.
Patent Landscape and Prior Art Consideration
Related Patents and Publications
The technology relates to the broader category of nucleoside and nucleotide analogs, which date back to the late 20th century.
-
Prior Art Publications: Similar compounds such as tenofovir and adefovir share structural similarities but differ in specific substitutions and stereochemistry, which the patent narrows down.
-
Patent Family Members: Gilead has filed multiple applications covering related compounds, methods, and synthesis processes, including US patents 9,948,737 and 9,981,617, which also focus on nucleoside analogs with antiviral activity.
Patentability and Novelty
- The specific stereochemistry and chemical substitutions claimed distinguish this patent from earlier compounds like tenofovir and its derivatives.
- The patent's claims are supported by data demonstrating improved stability, bioavailability, or antiviral efficacy, helping establish novelty and inventive step.
Competition and Infringement Risks
Competitors targeting similar chemical scaffolds face potential infringement unless they design around the specific claimed compounds. The patent landscape exhibits a pattern of overlapping claims from other pharmaceutical companies working on nucleotide prodrugs, such as Gilead's competitors in HCV and HBV antiviral space.
Strategic Position and Implications
The patent grants Gilead protection over a class of nucleoside phosphonate compounds for antiviral treatment, covering both the molecules and their methods of use. By claiming specific stereochemistry and substituents, Gilead maintains a competitive edge in the antiviral market.
The patent's broad claims on synthesis methods and compositions foster licensing opportunities or enforcement actions. Its expiration is expected around 2039–2040, considering patent term adjustments.
Summary Table
| Aspect |
Details |
| Patent Number |
10,195,278 |
| Grant Date |
January 29, 2019 |
| Assignee |
Gilead Sciences, Inc. |
| Claims |
Compound structures, methods of use, pharmaceutical compositions, synthesis processes |
| Focus |
Nucleoside phosphonate prodrugs for HBV/HCV |
| Patent Scope |
Class of compounds with specific stereochemistry and substitutions |
| Related Patents |
US9,948,737, US9,981,617, other family members |
| Patent Expiry |
Expected 2039–2040 |
Key Takeaways
- The patent claims a defined class of nucleoside phosphonate antivirals with specific stereochemistry.
- The scope covers chemical entities, their use in treating viral infections, and synthesis methods.
- It intersects with prior art but emphasizes novel stereochemical arrangements and substitutions.
- The patent landscape includes multiple family members, signaling a strategic patent estate around nucleoside antivirals.
- The patent provides Gilead with enforceable rights through 2039–2040, shaping competitive dynamics.
FAQs
1. Does the patent cover only specific chemical compounds?
Yes, it claims particular nucleoside phosphonate compounds with defined stereochemistry and substitutions.
2. Can competitors develop similar antivirals without infringing?
Potentially, if they design around specific claims—e.g., alter stereochemistry or substitutions—avoiding the scope of the patent.
3. What is the patent's strategic significance?
It protects key compounds intended for HBV and HCV treatments, securing market exclusivity during the patent term.
4. Are synthesis methods also protected?
Yes, claims include methods of making these compounds, providing broader protection.
5. When does this patent expire?
Likely around 2039–2040, accounting for patent term adjustments.
References
[1] United States Patent and Trademark Office. (2019). Patent No. 10,195,278.
[2] Gilead Sciences, Inc. Patent Family. (n.d.). Retrieved from USPTO database.
[3] Watanabe, T., et al. (2017). Advances in nucleoside and nucleotide analogs for viral infections. Journal of Antiviral Research, 144, 1-12.
